COVID-19 ventilator patients: higher infection risk?
NCT ID NCT04359693
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study from France compared over 1,500 ICU patients on ventilators to see if those with COVID-19 develop more lung infections than patients with influenza or no viral pneumonia. Researchers tracked cases of ventilator-associated pneumonia and tracheobronchitis. The goal is to understand if COVID-19 changes infection risk, which could improve care for critically ill patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If the findings show clear differences, this could help doctors better prevent and manage lung infections in ventilated COVID-19 patients.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. Results may not apply to all hospitals or patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,576 people
The number who actually took part.
- Started
-
Apr 2020
- Finished
-
Jul 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
patients suspected of pulmonary infection and admitted in ICU
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For all three groups: * Major patient * In patients in ICU * Patients intubated and mechanically ventilated for more than 48 hours. For the SARS-CoV2 group: community-acquired SARS-CoV2 pneumonia For the influenza group: community-acquired influenza pneumonia For the "No Viral Infection" group: no viral pneumonia on admission. Exclusion Criteria: * Refusal to participate * Lack of social security coverage
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Influenza pneumonia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Roger Salengro, ICU, CHU Lille
Lille, 59037, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Moderna tests Next-Generation mRNA COVID shot in babies and kids
- Can an old malaria drug help fight severe COVID-19?
- Can a new pill keep High-Risk COVID-19 patients out of the hospital?
- Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
- Millions of vaccine records scoured for rare side effects
- Scientists probe why lung disease raises COVID-19 risk